February 2017—Micromedic Technologies introduced CellDetect, a staining assay for the early detection of bladder cancer in urine specimens, to the U.S. market. The assay uses color and morphology to differentiate between normal and malignant cells. By highlighting early changes in neoplastic tumors, the color feature of CellDetect serves as an early indicator of malignancy, enhancing the diagnostic accuracy across all cancer stages. With its high sensitivity for low-grade, early stage tumors, the test provides critical adjunctive information supporting the management of bladder cancer patients, particularly for the early indication of recurrence in patients undergoing routine surveillance. Applying standard cytopathology equipment and processes, CellDetect is compatible with all standard urine smears.
Micromedic Technologies, 972-73-2753450